Target Pipelines
Subscribe to
our newsletters!
Showing 25–36 of 38 resultsSorted by latest
-
On demand upon order placementThis competitive intelligence report about Her3-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting Her3.€ 300.00
-
on demand upon order placementThis competitive intelligence report about DLL3-Targeted Therapy provides a competitor evaluation in the field of product candidates targeting delta-like ligand 3 (DLL3) as of August of 2025.€ 300.00
-
on demand upon order placementThis competitive intelligence report about B7-H3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting B7-H3 (or CD276) as of August of 2025.€ 300.00
-
on demand upon order placementThis competitive intelligence report about GPC3 Targeted Therapy provides a competitor evaluation in the field of product candidates targeting glypican-3 (GPC3) as of July of 2025.€ 400.00
-
on demand upon order placementThis competitive intelligence report about Fibroblast Activation Protein (FAP) Targeted Therapy provides a competitor evaluation in the field of product candidates targeting Fibroblast Activation Protein (FAP) as of July of...€ 300.00
-
on demand upon order placementThis competitive intelligence report Folate Receptor alpha (FRα) Targeted Therapy provides a competitor evaluation in the field of product and product candidates targeting Folate Receptor alpha as of July of...€ 200.00
-
on demand upon order placementThis competitive intelligence report about TL1A Inhibitors and DR3 Antagonists provides a competitor evaluation in the field of mostly antibodies targeting TNF-like ligand 1A (TL1A) or death receptor 3 (DR3) as...€ 200.00
-
on demand upon order placementThis competitive intelligence report about TSLP Inhibitors and TSLP Receptor Antagonists provides a competitor evaluation in the field of mostly antibodies targeting Thymic Stromal Lymphopoietin (TSLP) or its receptor as of...€ 300.00
-
on demand upon order placementThis Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
-
July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.Original price was: € 2550.00.€ 1800.00Current price is: € 1800.00.
-
July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
-
June of 2022The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00